Details for New Drug Application (NDA): 215102
✉ Email this page to a colleague
NDA 215102 describes BUSULFAN, which is a drug marketed by Accord Hlthcare Inc, Actavis, Am Regent, Amneal, Apotex, Arthur Grp, Eugia Pharma, Hospira, Meitheal, Mylan Institutional, Nexus, Norvium Bioscience, Pharmascience Inc, Prinston Inc, and Shilpa, and is included in fifteen NDAs. It is available from ten suppliers. Additional details are available on the BUSULFAN profile page.
The generic ingredient in BUSULFAN is busulfan. There are ten drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the busulfan profile page.
The generic ingredient in BUSULFAN is busulfan. There are ten drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the busulfan profile page.
Summary for 215102
| Tradename: | BUSULFAN |
| Applicant: | Eugia Pharma |
| Ingredient: | busulfan |
| Patents: | 0 |
Pharmacology for NDA: 215102
| Mechanism of Action | Alkylating Activity |
Medical Subject Heading (MeSH) Categories for 215102
Suppliers and Packaging for NDA: 215102
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BUSULFAN | busulfan | INJECTABLE;INJECTION | 215102 | ANDA | Eugia US LLC | 55150-395 | 55150-395-08 | 8 VIAL, SINGLE-DOSE in 1 CARTON (55150-395-08) / 10 mL in 1 VIAL, SINGLE-DOSE (55150-395-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 6MG/ML | ||||
| Approval Date: | Jun 25, 2024 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
